| 國立成功大學 |
2023 |
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|
Hurvitz, S.A.;Hegg, R.;Chung, W.-P.;Im, S.-A.;Jacot, W.;Ganju, V.;Chiu, J.W.Y.;Xu, B.;Hamilton, E.;Madhusudan, S.;Iwata, H.;Altintas, S.;Henning, J.-W.;Curigliano, G.;Perez-Garcia, J.M.;Kim, S.-B.;Petry, V.;Huang, C.-S.;Li, W.;Frenel, J.-S.;Antolin, S.;Yeo, W.;Bianchini, G.;Loi, S.;Tsurutani, J.;Egorov, A.;Liu, Y.;Cathcart, J.;Ashfaque, S.;Cort�s, J. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
Chen P.-J.; Furuse J.; Han K.-H.; CHIUN HSU; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. |
| 臺大學術典藏 |
2022-08-19T00:20:47Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y. |
| 臺大學術典藏 |
2022-08-19T00:20:45Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Cheng A.-L.; Han K.-H.; Jia J.-D.; Seong J.; CHIUN HSU; Chen B.-B.; Chen C.-H.; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W. |
| 臺大學術典藏 |
2022-08-19T00:20:37Z |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.; Ikeda M.; Chopra A.; Numata K.; Yeo W.; Kang Y.-K.; Hou M.-M.; Kim T.-Y.; Choo S.-P.; CHIUN HSU; Yau T. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Corrigendum to ��Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis�� [J Hepatol 71 (2019) 543�V552](S0168827819303009)(10.1016/j.jhep.2019.05.014)
|
Kudo M.; Dela Cruz C.; Anderson J.; Zhao H.; Chao Y.; Moriguchi M.; Kuromatsu R.; Ikeda M.; Yeo W.; Chopra A.; Yau T.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
YEN-SHEN LU; Yeo W.; Yap Y.-S.; Park Y.H.; Tamura K.; Li H.; Cheng R. |
| 臺大學術典藏 |
2022-02-23T02:12:26Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Hsu C.; Chen B.-B.; CHIEN-HUNG CHEN; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:16Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Hsu C.; Chen B.-B.; CHIEN-HUNG CHEN; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:50Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Hsu C.; Chen B.-B.; Chen C.-H.; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; ANN-LII CHENG |
